Compare AMRC & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRC | FTRE |
|---|---|---|
| Founded | 2000 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2010 | N/A |
| Metric | AMRC | FTRE |
|---|---|---|
| Price | $31.38 | $16.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $33.22 | $15.50 |
| AVG Volume (30 Days) | 527.2K | ★ 1.3M |
| Earning Date | 03-02-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.87 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | $1,883,767,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | $9.83 | $3.21 |
| Revenue Next Year | $9.83 | $0.25 |
| P/E Ratio | $25.69 | ★ N/A |
| Revenue Growth | ★ 12.22 | 1.88 |
| 52 Week Low | $8.49 | $3.97 |
| 52 Week High | $44.93 | $18.67 |
| Indicator | AMRC | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 48.20 | 45.80 |
| Support Level | $29.93 | $16.09 |
| Resistance Level | $34.01 | $17.20 |
| Average True Range (ATR) | 1.70 | 1.11 |
| MACD | -0.05 | -0.17 |
| Stochastic Oscillator | 31.50 | 29.71 |
Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of its revenue from the U.S. Regions segment.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.